Feasibility study of lncRNA DHRS4-AS1 sponge miR-222-3p in the diagnosis of thyroid cancer
Abstract
Introduction: Thyroid cancer is a commonly occurring malignant tumour within the endocrine system, the incidence of which has been increasing steadily in our country. It has been the focus and direction of research in recent decades to continuously explore the diagnostic markers and molecular mechanisms of thyroid cancer and provide new possibilities for the healing of patients. In this study, lncRNA DHRS4-AS1 was identified as the research target, and the regulatory function of abnormal expression of DHRS4-AS1 on thyroid cancer was discussed.
Material and methods: Thyroid cancer (116) and non-cancer normal (82) tissue samples were collected in this paper, and the expression of DHRS4-AS1 and miR-222-3p in tissues and cells were evaluated by RT-qPCR. CCK-8 and flow cytometry were used to detect cell survival status. The mechanism of DHRS4-AS1 sponge miR-222-3p was analysed by dual-luciferase reporter gene detection.
Results: In the present study, DHRS4-AS1 was down-regulated in both thyroid tissue and cell samples, while miR-222-3p expression was elevated. The ROC curve reflected the diagnostic value of DHRS4-AS1 in thyroid cancer [area under the curve (AUC) = 0.887, sensitivity = 76.7%, specificity = 95.1%]. DHRS4-AS1 regulates the development of thyroid cancer by targeting miR-222-3p. In addition, in vitro experiments demonstrated that overexpression of DHRS4-AS1 (pcDNA3.1-DHRS4-AS1) inhibited the proliferation of thyroid cancer cells and promoted cell apoptosis, while down-regulating the level of miR-222-3p.
Conclusions: DHRS4-AS1 acts as a miR-222-3p sponge in thyroid cancer, and overexpression of DHRS4 AS1 down-regulates cell proliferation and promotes cell apoptosis. These findings demonstrate the potential of DHRS4-AS1 as a diagnostic factor for thyroid cancer.
Keywords: thyroid cancerlncRNA DHRS4-AS1miR-222-3pdiagnosisproliferationapoptosis
References
- Bao WQ, Zi H, Yuan QQ, et al. Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Thorac Cancer. 2021; 12(18): 2494–2503.
- Tirrò E, Martorana F, Romano C, et al. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes (Basel). 2019; 10(9).
- Zhou Y, Zhao Y, Ding Xi, et al. A New Way Out of the Predicament of Anaplastic Thyroid Carcinoma From Existing Data Analysis. Front Endocrinol (Lausanne). 2022; 13: 887906.
- Asherloo H, Nabipoorashrafi SA, Kashanizadeh A, et al. Evaluation of Positive Predictors of Micrometastasis in Central Lymph Nodes in Patients with Papillary Thyroid Cancer; A Cross-Sectional Study. Iran J Pathol. 2022; 17(4): 442–447.
- Xiang C, Sun WH, Ke Y, et al. CDCA8 Contributes to the Development and Progression of Thyroid Cancer through Regulating CDK1. J Cancer. 2022; 13(7): 2322–2335.
- Sado J, Kitamura T, Sobue T, et al. JPHC Study Group. Risk of thyroid cancer in relation to height, weight, and body mass index in Japanese individuals: a population-based cohort study. Cancer Med. 2018; 7(5): 2200–2210.
- Wu Z, Han L, Li W, et al. With High-Risk Factors, Total Thyroidectomy is Preferred for Thyroid Cancer. Cancer Manag Res. 2020; 12(5): 3713–3719.
- Wang H, Jiang Y, Song J, et al. The risk of perchlorate and iodine on the incidence of thyroid tumors and nodular goiter: a case-control study in southeastern China. Environ Health. 2022; 21(1): 4.
- Wang Y, Wu Z, Li Y, et al. Long Non-Coding RNA H19 Promotes Proliferation, Migration and Invasion and Inhibits Apoptosis of Breast Cancer Cells by Targeting miR-491-5p/ZNF703 Axis. Cancer Manag Res. 2020; 12: 9247–9258.
- Li YJ, Li HY, Zhang Q, et al. The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma. Front Genet. 2022; 13: 942785.
- Deng Y, Wu J, Li X. lncRNA RUNDC3A-AS1 Regulates Proliferation and Apoptosis of Thyroid Cancer Cells via the miR-151b/SNRPB Axis. Int J Endocrinol. 2022; 2022: 9433434.
- Shan Y, He R, Yang X, et al. An autophagy-related lncRNA prognostic risk model for thyroid cancer. Eur Arch Otorhinolaryngol. 2022; 279(3): 1621–1631.
- Qi F, Tang J, Cai Z, et al. Long non-coding RNA CATIP antisense RNA 1 (lncRNA CATIP-AS1) downregulation contributes to the progression and metastasis of thyroid cancer via epithelial-mesenchymal transition (EMT) pathway. Bioengineered. 2022; 13(3): 7592–7606.
- Wang C, Wang G, Zhang Z, et al. The downregulated long noncoding RNA is protumoral and associated with the prognosis of clear cell renal cell carcinoma. Onco Targets Ther. 2018; 11: 5631–5646.
- Yang Y, Su Z, Song X, et al. Enhancer RNA-driven looping enhances the transcription of the long noncoding RNA DHRS4-AS1, a controller of the DHRS4 gene cluster. Sci Rep. 2016; 6: 20961.
- Cui X, Zhou S, Lin Y. Long non-coding RNA DHRS4 antisense RNA 1 inhibits ectopic endometrial cell proliferation, migration, and invasion in endometriosis by regulating microRNA-139-5p expression. Bioengineered. 2022; 13(4): 9792–9804.
- Zhou Y, Li K, Zou X, et al. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis. Bioengineered. 2021; 12(2): 10862–10877.
- Wang J, Zhanghuang C, Jin L, et al. Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary thyroid carcinoma: a population-based study. BMC Geriatr. 2022; 22(1): 736.
- Cai M, Ni WJ, Wang YH, et al. Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors. Front Oncol. 2022; 12: 906372.
- Hyun KR, Kang S, Lee S. Cost-of-Illness Trends Associated with Thyroid Disease in Korea. Endocrinol Metab (Seoul). 2014; 29(3): 257–269.
- Januś D, Wójcik M, Drabik G, et al. Ultrasound variants of autoimmune thyroiditis in children and adolescents and their clinical implication in relation to papillary thyroid carcinoma development. J Endocrinol Invest. 2018; 41(3): 371–380.
- Ramírez-Moya J, Wert-Lamas L, Acuña-Ruíz A, et al. Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor. Sci Rep. 2022; 12(1): 7706.
- Zhang X, Zhang X, Jia Q, et al. LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis. BMC Cancer. 2022; 22(1): 344.
- Pan YQ, Huang KS, Chong TH, et al. LINC01089 blocks malignant progression of thyroid cancer by binding miR-27b-3p to enhance the FBLN5 protein level. Discov Oncol. 2022; 13(1): 114.
- Zhang Ke, Lv J, Peng X, et al. Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis. Biosci Rep. 2019; 39(4).
- Yan F, Zhao W, Xu X, et al. LncRNA DHRS4-AS1 Inhibits the Stemness of NSCLC Cells by Sponging miR-224-3p and Upregulating TP53 and TET1. Front Cell Dev Biol. 2020; 8: 585251.
- Li L, Lai Q, Zhang M, et al. Long non-coding RNA DLGAP1-AS1 promotes the progression of gastric cancer via miR-515-5p/MARK4 axis. Braz J Med Biol Res. 2021; 54(8): e10062.
- Yang H, Lin HC, Liu H, et al. A 6 lncRNA-Based Risk Score System for Predicting the Recurrence of Colon Adenocarcinoma Patients. Front Oncol. 2020; 10: 81.
- Li S, Zhao F, He Y, et al. The Clinical Significance of Lncrna GAS5 And Mir-222-3p in Carotid Artery Stenosis. Heart Surg Forum. 2022; 25(4): E530–E535.
- Li Li, Lin X, Xu P, et al. LncRNA GAS5 sponges miR-362-5p to promote sensitivity of thyroid cancer cells to I by upregulating SMG1. IUBMB Life. 2020; 72(11): 2420–2431.
- Zhang C, Chang Q, Hu Y, et al. Hydroxyurea (HU)-induced apoptosis in the mouse fetal tissues. Histol Histopathol. 2003; 18(2): 387–392.
- Stojanović S, Dobrijević Z, Šelemetjev S, et al. MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum. Endocrine. 2023; 79(1): 98–112.
